Pennan M. Barry
Research Subjects
Pennan M. Barry has a total of 135 co-authors. Here are the top co-authors by number of shared publications:
Jennifer Flood
Tuberculosis Control Branch, California Department of Public Health, Richmond, California, USA
6 shared publicationsJanice Westenhouse
Tuberculosis Control Branch, Division of Communicable Disease Control, California Department of Public Health, Center for Infectious Diseases , Richmond, California , USA
4 shared publications- Shereen Katrak
Tuberculosis Control Branch, California Department of Public Health , Richmond, California
4 shared publications Kristen Wendorf
California Department of Public Health, Richmond, California; and
3 shared publicationsLisa True
California Department of Public Health Tuberculosis Control Branch , Richmond, California , USA
3 shared publications- Adam Readhead
Tuberculosis Control Branch, California Department of Public Health , Richmond, California
2 shared publications
Latest Publications
- Open Access
- 28 April 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (5)
Outcomes and Treatment-limiting Adverse Events of Patients Receiving BPaL and BPaL-FQ in California
Background: The regimen bedaquiline, pretomanid, and linezolid (BPaL), with or without moxifloxacin, is recommended for treating multidrug-resistant tuberculosis (MDR TB). We describe real-world outcomes and tolerability of BPaL, with or without fluroquinolone (BPaL-FQ) in the U.S. Methods: Using data collected by the California MDR TB Service for patients receiving BPaL and BPaL-FQ during 2020–2024, we analyzed favorable outcomes (cure or treatment completion), relapse, and adverse event frequency and severity. Results: Ninety-seven patients were started on any pretomanid-containing regimen during 2020–2024; 76 (78%) of these had pulmonary TB, 21 (22%) had concurrent or exclusive extrapulmonary disease. Sixty-nine patients received at least 4 weeks of BPaL or BPaL-FQ and had final outcome documented. Favorable treatment outcomes were reported in 64 (93%) patients overall and in more than 80% of patients in almost all subgroups, regardless of underlying resistance pattern, site of disease, or comorbidities. There were no microbiologically confirmed TB relapses. Two deaths occurred in patients receiving BPaL-FQ. Adverse events that led to a drug change occurred in 40% of patients and included peripheral neuropathy, cytopenias, gastrointestinal upset, and headache or dizziness. The majority were attributed to linezolid 600 mg daily and associated with linezolid trough above 2 µg/mL; fluroquinolones were also frequently implicated. Discussion: In a cohort of patients receiving BPaL or BPaL-FQ in California during 2020–2024, a majority had a favorable outcome. More than one third of patients required drug dosage change or discontinuation to complete therapy. Linezolid was the main driver of poor tolerability and regimen changes.
- 28 April 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (5)
Open AccessOutcomes and Treatment-limiting Adverse Events of Patients Receiving BPaL and BPaL-FQ in California
Background: The regimen bedaquiline, pretomanid, and linezolid (BPaL), with or without moxifloxacin, is recommended for treating multidrug-resistant tuberculosis (MDR TB). We describe real-world outcomes and tolerability of BPaL, with or without fluroquinolone (BPaL-FQ) in the U.S. Methods: Using data collected by the California MDR TB Service for patients receiving BPaL and BPaL-FQ during 2020–2024, we analyzed favorable outcomes (cure or treatment completion), relapse, and adverse event frequency and severity. Results: Ninety-seven patients were started on any pretomanid-containing regimen during 2020–2024; 76 (78%) of these had pulmonary TB, 21 (22%) had concurrent or exclusive extrapulmonary disease. Sixty-nine patients received at least 4 weeks of BPaL or BPaL-FQ and had final outcome documented. Favorable treatment outcomes were reported in 64 (93%) patients overall and in more than 80% of patients in almost all subgroups, regardless of underlying resistance pattern, site of disease, or comorbidities. There were no microbiologically confirmed TB relapses. Two deaths occurred in patients receiving BPaL-FQ. Adverse events that led to a drug change occurred in 40% of patients and included peripheral neuropathy, cytopenias, gastrointestinal upset, and headache or dizziness. The majority were attributed to linezolid 600 mg daily and associated with linezolid trough above 2 µg/mL; fluroquinolones were also frequently implicated. Discussion: In a cohort of patients receiving BPaL or BPaL-FQ in California during 2020–2024, a majority had a favorable outcome. More than one third of patients required drug dosage change or discontinuation to complete therapy. Linezolid was the main driver of poor tolerability and regimen changes.
- Open Access
- 27 November 2025
- Published by Elsevier in Journal of Clinical Tuberculosis and Other Mycobacterial Diseases
- Vol. 42, 100574
Central nervous system tuberculosis: characteristics, risks, and outcomes in California adults, 2010–2022
- 27 November 2025
- Published by Elsevier in Journal of Clinical Tuberculosis and Other Mycobacterial Diseases
- Vol. 42, 100574
Open AccessCentral nervous system tuberculosis: characteristics, risks, and outcomes in California adults, 2010–2022
- Top Cited PapersOpen Access
- 1 January 2025
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 211 (1) , 15-33
Updates on the Treatment of Drug-Susceptible and Drug-Resistant Tuberculosis: An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline
Background: On the basis of recent clinical trial data for the treatment of drug-susceptible and drug-resistant tuberculosis (TB), the American Thoracic Society, U.S. Centers for Disease Control and Prevention, European Respiratory Society, and Infectious Diseases Society of America have updated clinical practice guidelines for TB treatment in children and adults in settings in which mycobacterial cultures, molecular and phenotypic drug susceptibility tests, and radiographic studies, among other diagnostic tools, are available on a routine basis. Methods: A Joint Panel representing multiple interdisciplinary perspectives convened with American Thoracic Society methodologists to review evidence and make recommendations using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) and GRADE-ADOLOPMENT (adoption, adaptation, and, as needed, de novo development of recommendations) methodology. Results: New drug-susceptible TB recommendations include the use of a novel 4-month regimen for people with pulmonary TB and a shortened 4-month regimen for children with nonsevere TB. Drug-resistant TB recommendation updates include the use of novel regimens containing bedaquiline, pretomanid, and linezolid with or without moxifloxacin. Conclusions: All-oral, shorter treatment regimens for TB are now recommended for use in eligible individuals.
- 1 January 2025
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 211 (1) , 15-33
Top Cited PapersOpen AccessUpdates on the Treatment of Drug-Susceptible and Drug-Resistant Tuberculosis: An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline
Background: On the basis of recent clinical trial data for the treatment of drug-susceptible and drug-resistant tuberculosis (TB), the American Thoracic Society, U.S. Centers for Disease Control and Prevention, European Respiratory Society, and Infectious Diseases Society of America have updated clinical practice guidelines for TB treatment in children and adults in settings in which mycobacterial cultures, molecular and phenotypic drug susceptibility tests, and radiographic studies, among other diagnostic tools, are available on a routine basis. Methods: A Joint Panel representing multiple interdisciplinary perspectives convened with American Thoracic Society methodologists to review evidence and make recommendations using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) and GRADE-ADOLOPMENT (adoption, adaptation, and, as needed, de novo development of recommendations) methodology. Results: New drug-susceptible TB recommendations include the use of a novel 4-month regimen for people with pulmonary TB and a shortened 4-month regimen for children with nonsevere TB. Drug-resistant TB recommendation updates include the use of novel regimens containing bedaquiline, pretomanid, and linezolid with or without moxifloxacin. Conclusions: All-oral, shorter treatment regimens for TB are now recommended for use in eligible individuals.
- 26 March 2024
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 79 (1) , 223-232
Epidemiology and Treatment Outcomes of Tuberculosis With Chronic Hepatitis B Infection—California, 2016–2020
Background: Improved epidemiologic and treatment data for active tuberculosis (TB) with chronic hepatitis B virus (cHBV) infection might inform and encourage screening and vaccination programs focused on persons at risk of having both conditions.Methods: We matched the California Department of Public Health TB registry during 2016–2020 to the cHBV registry using probabilistic matching algorithms. We used chi-square analysis to compare the characteristics of persons with TB and cHBV with those with TB only. We compared TB treatment outcomes between these groups using modified Poisson regression models. We calculated the time between reporting of TB and cHBV diagnoses for those with both conditions.Results: We identified 8435 persons with TB, including 316 (3.7%) with cHBV. Among persons with TB and cHBV, 256 (81.0%) were non–US-born Asian versus 4186 (51.6%) with TB only (P < .0001). End-stage renal disease (26 [8.2%] vs 322 [4.0%]; P < .001) and HIV (21 [6.7%] vs 247 [3.0%]; P = .02) were more frequent among those with TB and cHBV compared with those with TB only. Among those with both conditions, 35 (11.1%) had TB diagnosed >60 days before cHBV (median, 363 days) and 220 (69.6%) had TB diagnosed >60 days after cHBV (median, 3411 days).Conclusions: Persons with TB and cHBV were found more frequently in certain groups compared with TB only, and infrequently had their conditions diagnosed together. This highlights an opportunity to improve screening and treatment of TB and cHBV in those at high risk for coinfection.
- 26 March 2024
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 79 (1) , 223-232
Epidemiology and Treatment Outcomes of Tuberculosis With Chronic Hepatitis B Infection—California, 2016–2020
Background: Improved epidemiologic and treatment data for active tuberculosis (TB) with chronic hepatitis B virus (cHBV) infection might inform and encourage screening and vaccination programs focused on persons at risk of having both conditions.Methods: We matched the California Department of Public Health TB registry during 2016–2020 to the cHBV registry using probabilistic matching algorithms. We used chi-square analysis to compare the characteristics of persons with TB and cHBV with those with TB only. We compared TB treatment outcomes between these groups using modified Poisson regression models. We calculated the time between reporting of TB and cHBV diagnoses for those with both conditions.Results: We identified 8435 persons with TB, including 316 (3.7%) with cHBV. Among persons with TB and cHBV, 256 (81.0%) were non–US-born Asian versus 4186 (51.6%) with TB only (P < .0001). End-stage renal disease (26 [8.2%] vs 322 [4.0%]; P < .001) and HIV (21 [6.7%] vs 247 [3.0%]; P = .02) were more frequent among those with TB and cHBV compared with those with TB only. Among those with both conditions, 35 (11.1%) had TB diagnosed >60 days before cHBV (median, 363 days) and 220 (69.6%) had TB diagnosed >60 days after cHBV (median, 3411 days).Conclusions: Persons with TB and cHBV were found more frequently in certain groups compared with TB only, and infrequently had their conditions diagnosed together. This highlights an opportunity to improve screening and treatment of TB and cHBV in those at high risk for coinfection.
- Open Access
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
1881. Costs of Treating Multidrug Resistant Tuberculosis in California, 2022
We estimated the cost of four regimens: an 18-month 5-drug regimen with an injectable agent but no bedaquiline (INJ18), a U.S. guideline-based 18-month 5-drug all oral regimen with bedaquiline (BDQ18), and two 6-month regimens: BPaL and BPaL plus moxifloxacin (BPaLM). We established a standardized set of services for each regimen, assumed no treatment side effects or treatment failure, and summed cost components in 2022 dollars. Cost components included inpatient care costs based on published literature, medication costs (340B and wholesale acquisition prices) paid by California public health TB programs, outpatient laboratory, imaging and physician fees based on California Medicaid reimbursement schedule, and case management (e.g., nurse case manager or outreach worker time, adherence incentives) based on published literature. Total direct cost for MDR TB care was $86,000-94,000 for BPaL, $86,000-96,000 for BPaLM, $117,000-187,000 for INJ18, and $127,000-203,000 for BDQ18. Hospitalization costs comprised the largest proportion of direct costs for BPaL/BPaM, regardless of type of drug pricing (47-53%) but were also a substantial component of other regimens (22-39% for BDQ18 and INJ18). Bedaquiline was the largest contributor to cost of medications for BPaL and BPaLM even with public health pricing. MDR TB care is costly. Despite high cost of medications, shorter BPaL/BPaLM regimens may provide cost savings. All Authors: No reported disclosures
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
Open Access1881. Costs of Treating Multidrug Resistant Tuberculosis in California, 2022
We estimated the cost of four regimens: an 18-month 5-drug regimen with an injectable agent but no bedaquiline (INJ18), a U.S. guideline-based 18-month 5-drug all oral regimen with bedaquiline (BDQ18), and two 6-month regimens: BPaL and BPaL plus moxifloxacin (BPaLM). We established a standardized set of services for each regimen, assumed no treatment side effects or treatment failure, and summed cost components in 2022 dollars. Cost components included inpatient care costs based on published literature, medication costs (340B and wholesale acquisition prices) paid by California public health TB programs, outpatient laboratory, imaging and physician fees based on California Medicaid reimbursement schedule, and case management (e.g., nurse case manager or outreach worker time, adherence incentives) based on published literature. Total direct cost for MDR TB care was $86,000-94,000 for BPaL, $86,000-96,000 for BPaLM, $117,000-187,000 for INJ18, and $127,000-203,000 for BDQ18. Hospitalization costs comprised the largest proportion of direct costs for BPaL/BPaM, regardless of type of drug pricing (47-53%) but were also a substantial component of other regimens (22-39% for BDQ18 and INJ18). Bedaquiline was the largest contributor to cost of medications for BPaL and BPaLM even with public health pricing. MDR TB care is costly. Despite high cost of medications, shorter BPaL/BPaLM regimens may provide cost savings. All Authors: No reported disclosures
- 1 February 2023
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 207 (3) , 336-345
Tuberculosis Diagnoses Following Wildfire Smoke Exposure in California
Rationale: Wildfires are a significant cause of exposure to ambient air pollution in the United States and other settings. Although indoor air pollution is a known contributor to tuberculosis reactivation and progression, it is unclear whether ambient pollution exposures, including wildfire smoke, similarly increase risk. Objectives: To determine whether tuberculosis diagnosis was associated with recent exposure to acute outdoor air pollution events, including those caused by wildfire smoke. Methods: We conducted a case-crossover analysis of 6,238 patients aged ≥15 years diagnosed with active tuberculosis disease between 2014 and 2019 in 8 California counties. Using geocoded address data, we characterized individuals’ daily exposure to <2.5 μm-diameter particulate matter (PM2.5) during counterfactual risk periods 3–6 months before tuberculosis diagnosis (hazard period) and the same time 1 year previously (control period). We compared the frequency of residential PM2.5 exposures exceeding 35 μg/m3 (PM2.5 events) overall and for wildfire-associated and nonwildfire events during individuals’ hazard and control periods. Measurements and Main Results: In total, 3,139 patients experienced 1 or more PM2.5 events during the hazard period, including 671 experiencing 1 or more wildfire-associated events. Adjusted odds of tuberculosis diagnosis increased by 5% (95% confidence interval, 3–6%) with each PM2.5 event experienced over the 6-month observation period. Each wildfire-associated PM2.5 event was associated with 23% (19–28%) higher odds of tuberculosis diagnosis in this time window, whereas no association was apparent for nonwildfire-associated events. Conclusions: Residential exposure to wildfire-associated ambient air pollution is associated with an increased risk of active tuberculosis diagnosis.
- 1 February 2023
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 207 (3) , 336-345
Tuberculosis Diagnoses Following Wildfire Smoke Exposure in California
Rationale: Wildfires are a significant cause of exposure to ambient air pollution in the United States and other settings. Although indoor air pollution is a known contributor to tuberculosis reactivation and progression, it is unclear whether ambient pollution exposures, including wildfire smoke, similarly increase risk. Objectives: To determine whether tuberculosis diagnosis was associated with recent exposure to acute outdoor air pollution events, including those caused by wildfire smoke. Methods: We conducted a case-crossover analysis of 6,238 patients aged ≥15 years diagnosed with active tuberculosis disease between 2014 and 2019 in 8 California counties. Using geocoded address data, we characterized individuals’ daily exposure to <2.5 μm-diameter particulate matter (PM2.5) during counterfactual risk periods 3–6 months before tuberculosis diagnosis (hazard period) and the same time 1 year previously (control period). We compared the frequency of residential PM2.5 exposures exceeding 35 μg/m3 (PM2.5 events) overall and for wildfire-associated and nonwildfire events during individuals’ hazard and control periods. Measurements and Main Results: In total, 3,139 patients experienced 1 or more PM2.5 events during the hazard period, including 671 experiencing 1 or more wildfire-associated events. Adjusted odds of tuberculosis diagnosis increased by 5% (95% confidence interval, 3–6%) with each PM2.5 event experienced over the 6-month observation period. Each wildfire-associated PM2.5 event was associated with 23% (19–28%) higher odds of tuberculosis diagnosis in this time window, whereas no association was apparent for nonwildfire-associated events. Conclusions: Residential exposure to wildfire-associated ambient air pollution is associated with an increased risk of active tuberculosis diagnosis.
- Open Access
- 12 January 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 23 (3) , 401-407
Solid organ transplant recipients with tuberculosis disease in California, 2010 to 2020
- 12 January 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 23 (3) , 401-407
Open AccessSolid organ transplant recipients with tuberculosis disease in California, 2010 to 2020
- Open Access
- 5 October 2022
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 9 (12) , ofac500
Low-Dose Linezolid for Treatment of Patients With Multidrug-Resistant Tuberculosis
Linezolid has been prioritized for treating multidrug-resistant TB (MDR TB), but toxicity limits its use. We report treatment outcomes for MDR TB patients in California who received standard dose linezolid versus those who switched to low dose. We include culture-positive MDR TB cases treated with linezolid and receiving California MDR TB Service consultation during 2009–2016. Demographic, clinical, and laboratory data are analyzed using univariate analysis to compare patients that received linezolid of different dosing strategies. Analysis endpoints are linezolid treatment duration (measure of tolerability), treatment success (completion or cure), and adverse events (AEs). Sixty-nine of 194 (36%) MDR TB patients met inclusion criteria. While all patients began linezolid treatment at 600 mg daily, thirty-nine (57%) continued at this dosage (standard dose) and 30 (43%) switched to 300 mg daily (29%) or intermittent dosing (14%) (low dose). Patients on standard dose linezolid were treated for 240 days compared to 535 for those on low dose (p < .0001). Sixty-three patients (91%) achieved treatment success, 2 (2.9%) died, 1 (1.5%) failed treatment, 1 (1.5%) stopped treatment due to side effects, and 2 (2.9%) were lost or moved. Treatment success was higher (p = 0.03) in the low dose group. Sixty-two patients experienced ≥1 hematologic (71%) or neurologic (65%) AE. Those on low dose experienced significantly (p = 0.03) fewer AEs per linezolid month after switching (0.32 versus 0.10). Patients who switched to low dose tolerated linezolid longer with better treatment outcomes and fewer recurring AEs.
- 5 October 2022
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 9 (12) , ofac500
Open AccessLow-Dose Linezolid for Treatment of Patients With Multidrug-Resistant Tuberculosis
Linezolid has been prioritized for treating multidrug-resistant TB (MDR TB), but toxicity limits its use. We report treatment outcomes for MDR TB patients in California who received standard dose linezolid versus those who switched to low dose. We include culture-positive MDR TB cases treated with linezolid and receiving California MDR TB Service consultation during 2009–2016. Demographic, clinical, and laboratory data are analyzed using univariate analysis to compare patients that received linezolid of different dosing strategies. Analysis endpoints are linezolid treatment duration (measure of tolerability), treatment success (completion or cure), and adverse events (AEs). Sixty-nine of 194 (36%) MDR TB patients met inclusion criteria. While all patients began linezolid treatment at 600 mg daily, thirty-nine (57%) continued at this dosage (standard dose) and 30 (43%) switched to 300 mg daily (29%) or intermittent dosing (14%) (low dose). Patients on standard dose linezolid were treated for 240 days compared to 535 for those on low dose (p < .0001). Sixty-three patients (91%) achieved treatment success, 2 (2.9%) died, 1 (1.5%) failed treatment, 1 (1.5%) stopped treatment due to side effects, and 2 (2.9%) were lost or moved. Treatment success was higher (p = 0.03) in the low dose group. Sixty-two patients experienced ≥1 hematologic (71%) or neurologic (65%) AE. Those on low dose experienced significantly (p = 0.03) fewer AEs per linezolid month after switching (0.32 versus 0.10). Patients who switched to low dose tolerated linezolid longer with better treatment outcomes and fewer recurring AEs.
- 6 May 2022
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 75 (12) , 2113-2118
A Cross-sectional Study of Patients With Extrapulmonary Tuberculosis and Normal Chest Radiographs — What Characteristics Were Associated With Sputum Culture Positivity?
Background: Recognizing pulmonary involvement in tuberculosis (TB) patients is necessary to prevent TB transmission. We describe frequency and characteristics of patients with extrapulmonary TB (EPTB), normal chest radiographs, and positive sputum culture. Methods: We analyzed data of patients ≥15 years of age with EPTB reported to the California TB registry during 2011–2017 with cultured sputum and normal chest radiographs using generalized linear modeling to estimate prevalence ratios associated with positive sputum culture. Demographic, behavioral, clinical characteristics, and testing were compared for patients with positive and negative sputum culture. Results: Of 1635 patients with EPTB and normal chest radiographs, 937 (57%) had sputum culture performed, and 127 (13%) patients had positive results for Mycobacterium tuberculosis complex. Patients with positive results were more likely to: be male, experience homelessness, use substances, have HIV, and have >1 disease site. Among 85 patients with HIV co-infection, 54% had positive culture results compared with 9.5% among 852 patients without HIV co-infection. Patients with EPTB in more than 1 site were also more likely to have a positive sputum culture. Conclusions: Culturing sputum from patients with EPTB identified pulmonary cases not detected by chest radiograph, particularly among patients with HIV or >1 disease site.
- 6 May 2022
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 75 (12) , 2113-2118
A Cross-sectional Study of Patients With Extrapulmonary Tuberculosis and Normal Chest Radiographs — What Characteristics Were Associated With Sputum Culture Positivity?
Background: Recognizing pulmonary involvement in tuberculosis (TB) patients is necessary to prevent TB transmission. We describe frequency and characteristics of patients with extrapulmonary TB (EPTB), normal chest radiographs, and positive sputum culture. Methods: We analyzed data of patients ≥15 years of age with EPTB reported to the California TB registry during 2011–2017 with cultured sputum and normal chest radiographs using generalized linear modeling to estimate prevalence ratios associated with positive sputum culture. Demographic, behavioral, clinical characteristics, and testing were compared for patients with positive and negative sputum culture. Results: Of 1635 patients with EPTB and normal chest radiographs, 937 (57%) had sputum culture performed, and 127 (13%) patients had positive results for Mycobacterium tuberculosis complex. Patients with positive results were more likely to: be male, experience homelessness, use substances, have HIV, and have >1 disease site. Among 85 patients with HIV co-infection, 54% had positive culture results compared with 9.5% among 852 patients without HIV co-infection. Patients with EPTB in more than 1 site were also more likely to have a positive sputum culture. Conclusions: Culturing sputum from patients with EPTB identified pulmonary cases not detected by chest radiograph, particularly among patients with HIV or >1 disease site.
- Open Access
- 14 August 2020
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 71 (4) , 1010-1016
Bedaquiline for the Treatment of Multidrug-resistant Tuberculosis in the United States
Background: In 2012, the Food and Drug Administration approved use of bedaquiline fumarate as part of combination therapy for multidrug-resistant tuberculosis (MDR TB). We describe treatment outcomes, safety, and tolerability of bedaquiline in our case series. Methods: Data on patients started on bedaquiline for MDR TB between September 2012 and August 2016 were collected retrospectively through 4 TB programs using a standardized abstraction tool. Data were analyzed using univariate methods. Adverse events were graded using the Common Terminology Criteria for Adverse Events. Results: Of 14 patients, 7 (50%) had MDR, 4 (29%) had pre–extensively drug-resistant (XDR), and 3 (21%) had XDR TB. All had pulmonary TB, 5 (36%) had pulmonary and extrapulmonary TB, and 9/13 (69%) were smear positive. One patient (7%) had HIV coinfection, 5 (36%) had diabetes mellitus, and 5/14 (36%) had previous treatment TB. All patients were non–US-born and 5/14 (36%) had private insurance. All patients achieved sputum culture conversion within a mean of 71 days (26–116); 5 after starting bedaquiline. Twelve (86%) completed treatment and 1 (7%) moved out of the country. One patient (7%) had QTc prolongation >500 milliseconds and died 20 months after discontinuing bedaquiline of a cause not attributable to the drug. Common adverse events were peripheral neuropathy 7/14 (50%), not customarily associated with bedaquiline use, and QTc prolongation 6/14 (43%). Conclusions: Of 14 patients, 1 (7%) had an adverse event necessitating bedaquiline discontinuation. Safety, culture conversion, and treatment completion in this series (7%) support use of bedaquiline for the treatment of MDR/XDR TB.
- 14 August 2020
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 71 (4) , 1010-1016
Open AccessBedaquiline for the Treatment of Multidrug-resistant Tuberculosis in the United States
Background: In 2012, the Food and Drug Administration approved use of bedaquiline fumarate as part of combination therapy for multidrug-resistant tuberculosis (MDR TB). We describe treatment outcomes, safety, and tolerability of bedaquiline in our case series. Methods: Data on patients started on bedaquiline for MDR TB between September 2012 and August 2016 were collected retrospectively through 4 TB programs using a standardized abstraction tool. Data were analyzed using univariate methods. Adverse events were graded using the Common Terminology Criteria for Adverse Events. Results: Of 14 patients, 7 (50%) had MDR, 4 (29%) had pre–extensively drug-resistant (XDR), and 3 (21%) had XDR TB. All had pulmonary TB, 5 (36%) had pulmonary and extrapulmonary TB, and 9/13 (69%) were smear positive. One patient (7%) had HIV coinfection, 5 (36%) had diabetes mellitus, and 5/14 (36%) had previous treatment TB. All patients were non–US-born and 5/14 (36%) had private insurance. All patients achieved sputum culture conversion within a mean of 71 days (26–116); 5 after starting bedaquiline. Twelve (86%) completed treatment and 1 (7%) moved out of the country. One patient (7%) had QTc prolongation >500 milliseconds and died 20 months after discontinuing bedaquiline of a cause not attributable to the drug. Common adverse events were peripheral neuropathy 7/14 (50%), not customarily associated with bedaquiline use, and QTc prolongation 6/14 (43%). Conclusions: Of 14 patients, 1 (7%) had an adverse event necessitating bedaquiline discontinuation. Safety, culture conversion, and treatment completion in this series (7%) support use of bedaquiline for the treatment of MDR/XDR TB.